AstraZeneca

News

AstraZeneca partners Health2Sync on CKD digital support tool

Taiwan-based digital health firm Health2Sync has added another big pharma company to the roster of clients for its patient support platform.

Oncology

Deep Dive: Oncology 2022

Eradicating cancer is an ambitious goal for oncologists and life science companies around the world.

News

AstraZeneca agrees $1.3bn deal to buy oncology player TeneoT...

AstraZeneca has signed a deal to buy US biotech TeneoTwo in a deal worth up to $1.27 billion that will boost its position therapies for haematological cancers.

News

AZ takes aim at BMS' lead in neoadjuvant NSCLC

Just weeks after Bristol-Myers Squibb claimed an FDA green light for Opdivo as a neoadjuvant therapy for non-small cell lung cancer, AstraZeneca is looking to encroach on its territory.

News

Data backs AZ's Wilson disease drug, but with a question mar...

Last year, AstraZeneca reported that a new drug to treat Wilson disease developed by its Alexion rare diseases unit had hit the mark in a phase 3 trial, setting it on course for regulatory

News

AZ preps FDA filing for $3.6bn amyloidosis drug eplontersen

Armed with new phase 3 data, AstraZeneca is preparing to file for regulatory approval of eplontersen, an antisense drug for one of the complications of the disease transthyretin amyloidosis

AstraZeneca partners Health2Sync on CKD digital support tool

Deep Dive: Oncology 2022

AstraZeneca agrees $1.3bn deal to buy oncology player TeneoT...

AZ takes aim at BMS' lead in neoadjuvant NSCLC

Data backs AZ's Wilson disease drug, but with a question mar...

AZ preps FDA filing for $3.6bn amyloidosis drug eplontersen

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

AstraZeneca

Editor's Picks